Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Duality Biotherapeutics, Inc. ( (HK:9606) ) just unveiled an update.
Duality Biotherapeutics has scheduled an extraordinary general meeting for April 29, 2026, in Shanghai, with shareholder participation governed by a defined book closure period. The company will close its register of members from April 24 to April 29, 2026, during which no share transfers will be registered, and will dispatch the meeting circular, notice, and proxy forms to shareholders, underscoring standard corporate governance and shareholder engagement practices.
To be eligible to attend and vote at the extraordinary general meeting, shareholders must ensure share transfers are lodged with the Hong Kong branch share registrar by 4:30 p.m. on April 23, 2026. The announcement formalizes the procedural timeline for investor participation in upcoming corporate decisions, signaling regulatory compliance and providing clarity for stakeholders on key administrative deadlines.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong under stock code 9606. The company operates in the life sciences sector, focusing on drug development and related biotherapeutic technologies, and maintains governance through a board comprising executive, non-executive, and independent non-executive directors.
Average Trading Volume: 814,513
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$28.01B
See more data about 9606 stock on TipRanks’ Stock Analysis page.